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An increased incidence of narcolepsy was seen in many countries after the pandemic H1N1 influenza
vaccination campaign in 2009e2010. The H1N1 vaccine e narcolepsy connection is based on observa-
tional studies that are prone to various biases, e.g., confounding by H1N1 infection, and ascertainment,
recall and selection biases. A direct pathogenic link has, however, remained elusive. We conducted a
systematic review and meta-analysis to analyze the magnitude of H1N1 vaccination related risk and to
examine if there was any association with H1N1 infection itself. We searched all articles from PubMed,
Web of Science and Scopus, and other relevant sources reporting the incidence and risk of post-vaccine
narcolepsy. In our paper, we show that the risk appears to be limited to only one vaccine (Pandemrix®).
During the first year after vaccination, the relative risk of narcolepsy was increased 5 to 14-fold in
children and adolescents and 2 to 7-fold in adults. The vaccine attributable risk in children and ado-
lescents was around 1 per 18,400 vaccine doses. Studies from Finland and Sweden also appear to
demonstrate an extended risk of narcolepsy into the second year following vaccination, but such con-
clusions should be interpreted with a word of caution due to possible biases. Benefits of immunization
outweigh the risk of vaccination-associated narcolepsy, which remains a rare disease.
© 2017 Elsevier Ltd. All rights reserved.Introduction
Narcolepsy is a complex chronic hypersomnia syndrome
affecting approximately 20e50 per 100,000 persons [1e4]. The
previously reported estimated incidence is approximately 1 per
100,000 persons per year with the peak of onset at the 2nd decade
[4e6]. Two distinct disease categories can be distinguished. Nar-
colepsy type 1 (NT1) is likely caused by an autoimmune-mediated
destruction of hypocretin-producing neurons in the lateral hypo-
thalamus [7,8]. NT1 is almost always associated with cataplexy. In
narcolepsy type 2 (NT2), there is no hypocretin deficiency or
cataplexy.
An increased incidence of narcolepsy was observed in six Eu-
ropean countries after the pandemic influenza A virus, A(H1N1)l Hospital, Department of
nland. Fax: þ358 9 440 260.
anen).pdm09 (“swine flu”), vaccination campaign during the winter
2009e2010. The first signal was observed in Finland and Sweden,
followed by France, England, Ireland, and Norway e all the coun-
tries where AS03-adjuvanted pandemic vaccine Pandemrix (Glax-
oSmithKline Biologicals, Wavre, Belgium) was widely used [9e15].
In the European Union and European Economic Area (EU/EEA),
three centrally and five nationally authorized vaccines were used
with coverage of at least 46.2 million people [15]. Five vaccines had
no adjuvant, two had MF59-adjuvant and one, Pandemrix, had
AS03 adjuvant. Pandemrix was the most used vaccine (over 30.5
million people vaccinated) in Europe. In the United States, over 90
million doses of pandemic H1N1 vaccination were administered in
2009e2010, but no adjuvanted vaccines were used [16].
One particular problem with the observational studies is their
proneness to various biases such as confounding by natural H1N1
infection, and ascertainment, recall and selection biases. For
instance, a seasonal and temporary increase in the incidence of
narcolepsy was also seen in China after the 2009e2010 pandemic
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T.O. Sarkanen et al. / Sleep Medicine Reviews 38 (2018) 177e186178influenza A virus without clear relation to any vaccine [17e19]. This
implicates the possibility that the H1N1 virus per se could be a
triggering factor for the development of narcolepsy at least in Asian
population. Furthermore, it was recently reported that influenza
virus is capable of damaging hypocretinergic neurons in immune-
depleted mice causing a narcolepsy-resembling phenotype [20].
Narcolepsy has also been a rare, underdiagnosed disease with
long delay between onset of symptoms and diagnosis [21]. There-
fore, the recognition of the syndrome may have been limited
especially among primary health care practitioners before
increased media attention after H1N1-related cases. Simply an in-
crease in attention towards this disease could lead to increase in the
number of diagnosed cases without an actual rise in incidence. The
methods in the observational studies are also somewhat hetero-
geneous. For example, incorrect case confirmation and inaccurate
gathering of information on the symptom onset and vaccination
date could cause ascertainment bias [22].
Even if observational studies could prove strong connection
between vaccination and narcolepsy, the true causative relation-
ship requires a pathogenic-proven link. However, specific biological
mechanisms behind the vaccine-associated narcolepsy are still
incompletely understood [8]. Some evidence exists on increased
immune response against viral nucleoprotein in Pandemrix in
subjects who have genetic predisposition to narcolepsy by HLA
DQB1*06:02 allele [23].
Taken into account biological and epidemiological controversies
in connection between narcolepsy, H1N1 influenza virus infections
and vaccinations, we conducted a systematic review and meta-
analysis to clarify the risk of narcolepsy associated with H1N1
vaccines and infections.
Methods
Literature search and selection criteria
We searched PubMed,Web of Science, and Scopus for all articles
reporting incidence and risk of Pandemrix H1N1-vaccination-
associated narcolepsy in November 2016 without a language
restriction. The full search string was (narcolepsy[MeSH] or nar-
colepsy) AND (vaccines[MeSH] OR vaccination[MeSH] OR influenza
[MeSH] or Pandemrix OR vaccines OR vaccination).
We also checked the references of all relevant studies and re-
view articles to identify additional sources. Webpages of National
Institute for Health and Welfare (THL) in Finland, Medical Products
Agency (MPA) in Sweden, Norwegian Medicines Agency, Health
Protection Surveillance Centre (HPSC) in Ireland, Public HealthEngland, Agence Nationale de Securite des Medicaments et des
Produits de Sante (ANSM) in France, and European Centre for Dis-
ease Control (ECDC) were checked for their reports on narcolepsy.
We followed Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines in conducting and reporting of the
study.
Eligibility criteria
Two authors (TS, MP) assessed the articles for eligibility based
on first the title, then the abstract, and finally the full text. We
included all studies and reports that evaluated the risk of nar-
colepsy or the number of narcolepsy cases after Pandemrix
vaccination. We also included studies assessing the risk of nar-
colepsy after other A(H1N1)pdm09 vaccines in the qualitative
synthesis. In case of overlapping data, the most recent and
comprehensive study was used. Only cases fulfilling Brighton
criteria 1e3 or International classification of sleep disorders 2
criteria for narcolepsy (excessive daytime sleepiness (EDS) and
low cerebrospinal fluid (CSF) hypocretin or positive multiple sleep
latency test (MSLT) were used in analysis) in order to avoid wrong
diagnoses [24].
Data extraction
Data extractionwas performed independently by two reviewers
(TS, MP). Any disagreement was solved by discussion. Data
extraction included: country or study area, author, publication year,
study type, age of subjects, duration of follow-up or collection
period, number of vaccinated and unvaccinated subjects, vaccina-
tion coverage, reported country-specific narcolepsy incidence rate
before and after 2009 influenza A H1N1 vaccination campaign in
vaccinated and unvaccinated subjects, relative risk (RR) in cohort
studies or odds ratio (OR) in caseecontrol studies, 95% confidence
interval (CI), and vaccine attributable risk of narcolepsy. In the
analyses, relative risks and odds ratios were used interchangeably
because narcolepsy is a rare disease and in such cases these two
ratios are very close to each other.
Dutch population data were retrieved from Statistics
Netherlands and Swiss population data from Swiss Federal Statis-
tics Office for calculations of RR in these countries. There is limited
information on the incidence of narcolepsy in toddlers but for the
Netherlands reports, background incidence was evaluated to be
approximately 1 per 800,000 children aged less than five year
based on vaccine adverse event surveillance & communication
(VAESCO) data [15].
T.O. Sarkanen et al. / Sleep Medicine Reviews 38 (2018) 177e186 179Risk of bias in individual studies
Observational studies are prone to various ascertainment, recall
and selection biases (e.g., lack of blinding to vaccination status, lack
of validation of cases, and increased media attention) but also to
confounding such as H1N1 infection per se. We reviewed and
detailed on those potential biases for all the post-Pandemrix nar-
colepsy studies.
Statistical analysis
Statistical analyses were performed using STATA version 14.1
(StataCorp. 2015. Stata Statistical Software: Release 14. College Sta-
tion, TX, USA: StataCorp LP). Relative risks or odds ratios were used
for pooled analysis of all included studies. The results are presented
with 95% confidence intervals (CI) using a random-effects model.




Literature search resulted in 310 articles (Fig. 1) after removal of
duplicate papers. Additional ten articles were included outside of
the search as explained in the methods section [12,15,25e32].Records identified through 
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Fig. 1. PRISMA flow diagram of included studies. FIN, Finnish; SWE, Swedish; ENG, English
English titles and/or abstracts screened for relevant information.Seventy-five reviews were excluded, but their reference lists were
examined to include any appropriate articles not retrieved in the
literature search. After screening for the titles and abstracts, full
texts of 78 articles were read. Forty-nine studies either analyzed
duplicate populations with the studies included in the final analysis
or were not relevant. Eleven studies or reports were included in the
final meta-analysis (Table 1) [9e12,14,29,31,33e35]. Three addi-
tional Pandemrix studies [13,36,37], and fifteen non-Pandemrix
studies were included in the qualitative synthesis (Table 2)
[17e19,32,38e48].
The majority of the studies analyzed comprised of register
cohort studies (Table 1). Two case-coverage studies and one case-
econtrol study were also included. We also added a paper from
Netherlands Pharmacovigilance Centre reporting cases of narco-
lepsy in children aged six months to five years after Pandemrix
vaccination [31]. Only children with confirmed narcolepsy (Brigh-
ton classes 1e3) and onset after Pandemrix vaccination were
included in meta-analysis from this study (7 out of 20 reported
cases). We analyzed the studies divided into two subgroups: 1)
children and adolescents, and 2) adults.
Index dates and study period
Five different index dates were used in the studies: onset of
symptoms, first healthcare contact, referral to specialist, referral to
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; FRE, French. A 2 Norwegian, 4 Danish, 1 Geman, 1 Portuguese, 1 Russian, 1 Turkish.
Table 1
Summary of included Pandemrix studies in the meta-analysis.
Authors, reference number Country Type Age group
(y)
Follow-up period Number of subjects or follow-up years
Vaccinated Unvaccinated
Start End NC Healthy NC Healthy
Children and adolescents
Dauvilliers Y. et al., 2013 [33] France CC <18 Apr 1, 2009 Apr 30, 2011 21 N/Aa 14 N/Aa
Heier M. et al., 2013 [10] Norway RC 4e19 Nov 1, 2009 Dec 31, 2011 1st y 48 470,000 3 470,000
2nd y 5 470,000 2 470,000
Jokinen J. et al., 2014 [30] Finland RC 4e19 Jan 1, 2009 Dec 31, 2012 1st y 93 687,000 7b 692,000b
1e2 y 33 687,000 “ “
>2 y 13 751,000 “ “
Lareb 2015 [31] The Netherlands Report 0.5e5 7 589,000 NA 450,000c
Miller E. et al., 2013 [11] England CCov 4e18 Jan 1, 2008 Jul 31, 2011 11 360,000 64 8,130,000
MPA 2011 [12] Sweden RC <20 Jan 1, 2009 Dec 31, 2010 69 1,624,000 7 1,093,000
Nohynek H. et al., 2012 [9] Finland RC 4e19 Jan 1, 2009 Aug 15, 2010 46 511,000 7 986,000
O'Flanagan D. et al., 2014 [14] Ireland RC 5e19 Apr 1, 2009 Dec 31, 2010 19 160,000 5 620,000
Persson I. et al., 2013 [34] Sweden RC 0e20 Oct 1, 2009 Dec 31, 2011 126 966,000 425,000
Adults
Dauvilliers Y. et al., 2013 [33] France CC 18 Apr 1, 2009 Apr 30, 2011 11 N/A 16 N/A
Jokinen J. et al., 2013 [29] Finland RC 20e65 Jan 1, 2009 Dec 31, 2011 24 3,151,477 14 6,705,173
Jokinen J et al., 2014 [30] Finland RC 20e74 Jan 1, 2009 Dec 31, 2012 1st y 17 1,841,000 7b 5,802,000b
1e2 y 15 1,841,000 “ “
>2 y 2 1,825,000 “ “
O'Flanagan D. et al., 2014 [14] Ireland RC 20 Apr 1, 2009 Dec 31, 2010 2 470,000 1 2,850,000
Persson I et al., 2013 [34] Sweden RC 21e30 Oct 1, 2009 Dec 31, 2011 23 310,000 NA 428,000
31e40 18 445,000 NA 361,000
>40 40 1,627,000 NA 1,283,000
Stowe J. et al., 2016 [35] England CCov 18 Sep 1, 2009 Oct 30, 2011 5 650,000 35 1,340,000
NC, narcolepsy; CC, caseecontrol; RC, register cohort; CCov, case-coverage; N/A, not applicable; NA, not available.
a Number of vaccinated and unvaccinated subjects cannot be given because of the caseecontrol design.
b Number of unvaccinated cases reported for the full follow-up period until the end of 2012.
c Estimated from Statistic Netherlands.
Table 2
Summary of narcolepsy incidence studies from countries where Pandemrix vaccination was not used.
Authors, reference
number






Choe Y. et al., 2012 [38] South Korea Ecological Jul 2006 to Jun 2011 MF59-ADJ, non-ADJ 26.10%f Not increased
Duffy J. et al., 2014 [40] US Register cohort Oct 2009 to Dec 2011 Non-ADJa ~10% Not increased (OR ~1 in different
age groups).
Han F. et al., 2011 [17] Beijing, China Case series 1996e2011 Non-ADJ 5.6% 3-fold increase, not associated with
vaccination
Han F. et al., 2013 [18] Beijing, China Case series 1998 to Sep 2012 Non-ADJ 5.6% Risk reduced to normal after 2 y
Harris T. et al., 2014 [43] Ontario, Canada Reported adverse
effectsd
Until Apr 2013 AS03-ADJb 37%e Not increased
Kim W.J. et al., 2015 [44] South Koreag Ecological 2007e2013 MF59-ADJ, non-ADJ NR Not increased
Montplaisir J et al., 2014 [46] Quebec, Canada CC, S-CCS, RC Jan 2009 to Dec 2010 AS03-ADJb 57% Small increase possiblec
Tsai T.F. et al., 2011 [48] Worldwide Reported adverse
effects
Until Jul 2010 MF59-ADJ N/A Not increased
Wu H. et al., 2014 [19] Shanghai, China Case series 2003e2012 Non-ADJ NR 3-fold increase, not associated with
vaccination
ADJ, adjuvanted; OR, odds ratio; CC, case control, S-CCS, self-controlled case series; RC, register cohort; RR, relative risk; NR, not reported, N/A, not applicable.
a Monovalent inactivated vaccine and monovalent live attenuated influenza vaccine during the pandemic period in 2009, and trivalent inactivated vaccine and live
attenuated influenza vaccine during the seasonal influenza vaccination campaign in 2010e2011.
b Arepanrix (GlaxoSmithKline Inc, Missisauga, Ontario, Canada; GlaxoSmithKline Biologicals, Wavre, Belgium).
c RR 16 wk after vaccination CC 1.48 (0.37e7.03), S-CCS 2.96 (0.71e12.39), RC 4.32 (1.50e11.12). Attributable risk 1 per million vaccine doses.
d From Pharmacovigilance databases and clinical trials.
e Based on the number of distributed vaccines, not administered.
f 87% in age group under 18 y.
g Active duty soldiers and military officers in the Korean military.
T.O. Sarkanen et al. / Sleep Medicine Reviews 38 (2018) 177e186180most natural and ideal index date, but it is difficult to assess
objectively in retrospect and it is possibly prone to a recall bias. The
symptom onset was used as the primary index date in the Nor-
wegian and British studies, while it was included in sensitivity
analyses in the other studies [10,11]. The first health care contact
confirmed from patient records is the earliest objective time point
to be used as the index date. It was used in the primary analysis in
the Finnish and Irish studies [9,14,29,30]. These studies were theonly studies reporting also the referral to specialist as the index
date. The referral to MSLT was reported only in the French study
where it was also the primary index date [33]. The date of diagnosis
was used as the primary date in the Swedish studies [12,34].
Different study periods with the ending point from August 2010
to the end of year 2012 were used based on the time of publication
of the study and media awareness of the link between vaccination
and narcolepsy (to minimize ascertainment bias, see Discussion).
T.O. Sarkanen et al. / Sleep Medicine Reviews 38 (2018) 177e186 181Risk of post-vaccination narcolepsy
The total number of narcolepsy cases in included studies was
376 vaccinated and 95 unvaccinated children and adolescents. Total
follow-up number of vaccinated children and adolescents were 5.1
million, and unvaccinated 11.3 million person years. For adults, the
corresponding figures were 133 vaccinated, 59 unvaccinated nar-
colepsy cases, and 9.0 million follow-up vaccinated healthy adults
and 12.1 million follow-up unvaccinated healthy adults (Table 1).
In children and adolescents, RR of post-Pandemrix narcolepsy
during the primary analysis period was 14.32 (95% CI 8.92 to 22.99)
if the onset of symptomswas used as the index date. Corresponding
figures were 9.68 (4.88, 19.23) if the first healthcare contact, and
5.02 (3.36, 7.51) if the diagnosis was used as the index date (Fig. 2).
In adults, RR was 7.01 (3.40, 14.46) using the onset, 8.08 (3.86,
16.89) using the healthcare contact, and 2.95 (1.88, 4.62) using the
diagnosis as the index date (Fig. 3).
Heterogeneity measured by I2 statistic was very low, 0% in all
subgroups, except for the healthcare contact in children and ado-
lescents where I2 ¼ 44.1%, nevertheless, it was statistically insig-
nificant (P ¼ 0.167).
The vaccine attributable risk approximately one year after the
vaccination could be calculated from five studies in children and
adolescents [9e12,14]. Only a crude estimate can be given because
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Fig. 2. Forest plot of studies assessing the risk of narcolepsy related to Pandemrix vaccine
interval.calculation made from number of exposed and unexposed cases
and healthy subjects indicates an approximate 1 case per 18,400
vaccines (95% CI 1 per 16,700,1 per 20,400) or 5.4 cases per 100,000
vaccines. In adults, the small number of cases, except for Jokinen
et al. study, makes calculations less robust; vaccine attributable risk
based in Jokinen et al., Stowe et al., and O'Flanagan et al. studies was
1 per 181,000 (95% CI 1 per 141,000, 1 per 254,000), using the
healthcare contact as the index date in all three studies. These
calculations were made from primary follow-up periods, which
ended from August 2010 to April 2011.
Narcolepsy risk estimates after a year from the initial vaccina-
tion were available only from Finnish and Swedish register studies
[12,29,30,34]. In Finland, RR based on healthcare contact in one to
two years after the vaccination was 4.7 (2.2, 11.7) in children and
adolescents, and 6.8 (2.8, 17.7) in adults, returning to baseline in
two years after vaccinations. In Sweden, RR based on diagnosis after
at least one year from the vaccination was 2.66 (1.50, 4.72) in
subjects aged less than 20 y, and 2.24 (0.86, 5.85) in subjects aged
21e30 y. Still, onset of symptoms occurred most often during the
first three to six months following vaccination.
Synthesis of Pandemrix studies not included in meta-analysis
A four-year status of narcolepsy after H1N1 vaccination in
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Fig. 3. Forest plot of studies assessing the risk of narcolepsy related to Pandemrix vaccine in adults using different index dates. ES, Effect size; CI, Confidence Interval.
T.O. Sarkanen et al. / Sleep Medicine Reviews 38 (2018) 177e186182Research Society meeting of 2014 [36]. The authors reported some
vaccine-related adult cases and a decreased incidence in
2012e2013 compared to 2010e2011.
In a survey of 29/30 sleep centers in Switzerland, where only
adults (18e60 y) were vaccinated with Pandemrix, seven post-
Pandemrix narcolepsy cases and one case after a vaccination with
Focetria were found [37]. Overall vaccination coverage was
approximately 17% and Pandemrix was used in 60% of vaccinations
yielding approximately 400,000 to 500,000 vaccinated subjects.
Mean diagnostic delay in the survey was 13.4 mo and six out of
eight patients were diagnosed in 2010.Table 3
Number of narcolepsy cases in non-Pandemrix-studies.
Authors, reference number Vaccinated Non-vaccinated
NC Healthy NC Healthy
Duffy J. et al., 2014 [40] 2 650,000 NA NA
Han F. et al., 2011 [17] 8 NA 134 NA
Harris T. et al., 2014 [43] 0 4,800,000 N/A N/A
Montplaisir J. et al., 2014 [46] 8 4,500,000 16 3,400,000
Tsai T.F. et al., 2011 [48] 0 79,000 N/A N/A
NC, narcolepsy; NA, not available; N/A, not applicable.Synthesis of non-Pandemrix studies
No other vaccines outside of Pandemrix demonstrated clear
narcolepsy association. In Quebec, Canada, where AS03-adjuvanted
Arepanrix vaccine was used, reported RR in 16 wk after the vacci-
nation was 1.48 (0.37e7.03) using a caseecontrol method, 2.96
(0.71e12.39) using a self-controlled case-series method, and 4.32
(1.50e11.12) using a cohort method, yet vaccine attributable risk
was only 1 per 1,000,000, which is significantly lower than in Eu-
ropean studies (Tables 2 and 3) [46]. Post-marketing safety data
from Ontario, Canada, does not support an increased risk of nar-
colepsy associated with Arepanrix, either [43]. An increased risk
was not seen in South Korea or in the US, where Pandemrix vaccine
was not used [38,40,41,44]. Pharmacovigilance database explora-
tions or spontaneous reports have not shown increased risk ofnarcolepsy associated with MF59-adjuvanted vaccines with esti-
mated over 23 million administered doses [32,48].
There also appears to be some evidence of rising incidence of
narcolepsy in relation to H1N1, but disjointed from vaccination. In
Beijing and Shanghai area, there was a 3-fold increase during the
post-pandemic period unrelated to any vaccine that suggests a
temporal association between a peak in H1N1 infection and a peak
in narcolepsy incidence 3e6 mo later [17e19]. This incidence
decreased back to baseline two years after the H1N1 pandemic
suggesting that infectionwith the 2009 H1N1 strainwas associated
with narcolepsy onset. Also in Germany, an age-standardized
adjusted incidence rate increased more than three-fold between
pre- and post-pandemic periods [47]. The increase started already
in the spring 2009, and the incidence density ratio was 3.57 (95% CI
1.94, 7.00). The study was, however, based only on non-validated
register diagnoses and no vaccine history was available. The over-
all vaccine coverage in Germanywas 4e8%, mostlywith Pandemrix.
T.O. Sarkanen et al. / Sleep Medicine Reviews 38 (2018) 177e186 183Differences between vaccinated and unvaccinated narcolepsy
subjects
Clinical characteristics of the patients were reported in four risk-
association studies and four separate papers (Table 4)
[10,14,33,49e51]. Studies differed in evaluation of differences be-
tween vaccinated and unvaccinated narcolepsy subjects. For
instance, there was a shorter diagnostic delay and shorter time
from EDS to cataplexy in Finland and France, more prevalent cat-
aplexy near the disease onset in the UK, and a presence of multiple
symptoms at the disease onset in Sweden in the vaccinated sub-
jects. All these slight differences in clinical and polysomnographic
features greatly relate to disease duration and make it difficult to
determine the direct effect of Pandemrix.
Discussion
In this meta-analysis we found a 5- to 14-fold increase in inci-
dence of narcolepsy in children and adolescents and a 3- to 7-fold
increase in adults in the countries where Pandemrix vaccine was
widely used in 2009e2010 (Finland, France, Ireland, the
Netherlands, Norway, Sweden and the UK). The risk in the obser-
vational studies is dependent on the used index date. Use of onset
of symptoms as index date produced the highest risk followed by
date of healthcare contact, referral to sleep studies, and date of
diagnosis. The vaccine attributable risk of narcolepsy was signifi-
cant especially in children and adolescents (1 per 18,400). In HLA
DQB1*06:02 positive individuals, this would transfer to the risk of
approximately 1 per 4500 doses (0.022% per dose) considering that
the frequency of HLA DQB1*06:02 allele in general population is
around 25%. It seems that the risk window for the vaccine-induced
narcolepsy was as long as two years, but this finding needs to be
interpreted with caution because of possible biases and lack of
studies confirming this finding.
Heterogeneity in our meta-analysis was very low, except for
children and adolescent subgroup with the first healthcare contact
as the index date, although insignificant P-value (I2 ¼ 44%,
P ¼ 0.167) discredits a true heterogeneity. Miller et al's. study may
possibly have caused heterogeneity by the different design (case-
coverage vs. cohort and caseecontrol) and the different case
collection method (contact with sleep centers vs. national or
regional registries) [11].
Observational studies are prone to various other biases such as
ascertainment, recall and selection biases, and confounding. Post-
Pandemrix narcolepsy studies are no exception [52e54]. Ascer-
tainment bias could be caused by the lack of blinding to vaccinationTable 4
Comparison of demographic, clinical characteristics, and HLA typing between the
total number of vaccinated and unvaccinated children and adolescent narcolepsy
cases [10,12,14,33,49e51].
Vaccinated Unvaccinated P
Females 129/244 (53%) 53/113 (47%) 0.294
Cataplexy 194/206 (94%) 63/80 (79%) <0.001
Hypnagogic hallucinations 65/178 (37%) 59/102 (58%) 0.001
Sleep paralysis 31/158 (20%) 28/102 (27%) 0.141
Disturbed sleep 87/121 (72%) 63/102 (62%) 0.108
Behavioral problems 52/147 (35%) 23/72 (32%) 0.615
Rapid weight gain near onset 89/170 (52%) 39/102 (38%) 0.024
HLA DQB1*06:02 positive 144/147 (98%) 58/65 (89%) 0.006
CSF hypocretin <110 pg/mL 108/110 (98%)a 19/22 (86%) 0.008
CSF, cerebrospinal fluid.
All the reported figures represent only cases for which the characteristic was re-
ported, not the whole study population.
Statistically significant differences (P < 0.05) in bold.
a In vaccinated group one subject with hypocretin level of 121 pg/mL and one
“borderline”.status, the lack of validation of cases, or by the increased media
attention. Increased awareness of narcolepsy and confounding are
particularly interesting with respect to this matter. Bias caused by
media attention could be affected by collection or follow-up pe-
riods in the studies. Exactly identical follow-up periods could not
be obtained from the papers. Most studies reported at least the risk
during the first year following vaccination and this period was also
used in the primary quantitative meta-analysis. In Nohynek et al's.
study, the follow-up period ended already in August 2010 to avoid
possible bias caused by media attention [9]. If the follow-up period
was extended to December 2010, the decrease in risk ratio was
rather modest, from 12.7 (6.1, 30.8) to 11.4 (5.6, 27.5). It is unlikely
that the original risk ratio would have been explained by the
increased awareness only, as the risk was still clearly elevated. On
the other hand, a similar increased awareness was raised also in
Sweden, Norway, and France, while in these studies the follow-up
period lasted until the end of 2010 or 2011. Therefore, a small
bias due to the increased awareness cannot be excluded in these
studies [9,10,12,33,34]. In the studies from the UK and Ireland, even
if the follow-up period was longer, the media impact was probably
weak, as there was no increased media attention in these countries
demonstrated by Google searches, for instance [11,14]. The risk of
post-Pandemrix narcolepsy in these countries was comparable
with other studies also implying that increased media awareness
cannot fully explain the connection.
Most studies were conducted using ICSD-2 classification in
which narcolepsy is divided into narcolepsy-cataplexy and narco-
lepsy without cataplexy. The updated ICSD-3 was published in
2014, after most of the studies used in meta-analysis. In ICSD-3
narcolepsy categories are narcolepsy type 1 (NT1) characterized
by hypocretin deficiency (typically including cataplexy), and nar-
colepsy type 2 (NT2) with normal hypocretin levels, and no cata-
plexy. Brighton criteria are a classification based on level of
diagnostic certainty of narcolepsy [24]. Brighton classification level
1 denotes narcolepsy with proven hypocretin deficiency proven by
lumbar puncture. Level 2 includes cases with unambiguous cata-
plexy and positive sleep study findings (mean sleep latency inMSLT
8 min and two or more sleep onset REM sleep periods). Level 3
equals level 2 but without cataplexy in the absence of other
mimicking disorders. It is common that cataplexy develops several
months after onset of EDS. Therefore, Brighton classification levels
1 and 2 and also 3 can be considered accurate. Using Brighton and
ICSD-2 criteria for the diagnosis ascertainment reduces possible
bias caused by lack of blinding, since diagnosis is based on objective
sleep studies and/or cerebrospinal fluid analysis which are not
dependent on reviewers' subjective opinion. The only exception in
case verification was National Patient Register based study by
Persson et al., but most diagnoses retrieved had been validated
against case data in the previous study by the MPA [12,34]. Also in
the Dutch data, we chose only confirmed cases with Brighton
classification levels 1 to 3. We also ignored the cases that had their
onset before vaccination. This resulted in 7 out 20 reported cases.
Therefore, probability of false positives seems rather low. None-
theless, blinding to vaccination status in conduction of the chart
review may be difficult. Bias is possible if reviewers classify vacci-
nated cases more often as having narcolepsy than unvaccinated
cases.
We chose three index dates to be included in our analysis: onset
of symptoms, healthcare contact, and diagnosis. The exact date of
onset of symptoms is often difficult to remember and it is prone to a
recall bias. Moreover, narcolepsy manifests as a heterogeneous
clinical syndrome with either severe and abrupt symptom onset or
a more progressive development often described in adults, with
several months or years between daytime sleepiness and cataplexy
onset [55]. The patient's first healthcare contact regarding
T.O. Sarkanen et al. / Sleep Medicine Reviews 38 (2018) 177e186184narcolepsy symptoms could be a more objective measure, but it
was not reported in all the studies. The date of diagnosis is probably
the most easily obtained index date (from registries or patient re-
cords) but since the delay between onset and diagnosis can be very
variable and rather long (i.e., 8e12 y in recent EU countries [53]),
using only the diagnosis as the index date could also cause a bias.
Recall bias could affect the onset date and vaccination status if
obtained only from the patient. In most of the studies, vaccination
registries were used and using the healthcare contact as the index
date should decrease a recall bias as well. Using dates of referral to
specialist, referral to MSLT, or diagnosis as index dates could result
in the exposuremisclassification, if the subject was vaccinated after
the symptom onset but before these dates and would therefore be
classified as “exposed”. Variation in the diagnostic delay makes the
temporal association between vaccination and narcolepsy difficult
to investigate.
There were also some variations in defining the age groups. In
most of the studies, the youngest patients or controls were four to
five years old, and the age group division to young and adults was
made using 17e20 y of age. Lareb report was an exception with the
youngest patients being only two to four years of age [31]. In the
Netherlands, Pandemrix was used only in children aged 0.5e5
y with a very low incidence of idiopathic narcolepsy (i.e., without
vaccination) in this specific age group. Relative risk calculated from
this report was similar to other included studies suggesting an
increased risk of Pandemrix-associated narcolepsy also in this age
group. However, those results should be interpreted with caution
because of the lack of previous epidemiological and confirmed data.
We used VAESCO and Statistic Netherlands data for background
incidence rate approximation in the Netherlands.
To ensure comprehensives, we searched thoroughly all available
English and non-English sources reporting incidence of narcolepsy
after H1N1 infection or vaccination. Reports from all countries
where Pandemrix was used in large amounts have been included.
We have also included significant number of studies from countries
where other vaccines were used in the qualitative analysis. We
considered using funnel plots and e.g., Egger and Beggs test to
detect publication bias but, unfortunately, number of our studies is
limited (less than 10 per age group) which makes these test inac-
curate [56].
Data and differences on clinical presentation of Pandemrix-
associated and idiopathic narcolepsy need to be interpreted with
caution. It is possible that subjects with a more severe phenotype
are diagnosed earlier after the vaccination than those with milder
symptoms (Table 4). The disease course between idiopathic and
Pandemrix-associated narcolepsy seemed similar in a recent study
[57]. Vaccine associated cases are characterized by high frequency
of HLA DQB1*06:02, cataplexy and hypocretin deficiency. Currently,
no data supports increased risk of NT2 after Pandemrix or any other
vaccine.
The question of role and impact of potential confounding by
concomitant or previous A(H1N1)pdm09 infection is interesting
and also rather controversial. If an H1N1 infection had been the
major causative factor, one would expect to see an increased inci-
dence also in other countries than in those where Pandemrix was
used. So far, an increasewithout vaccination has been reported only
in China [17e19]. In Germany, a modest increase in the incidence of
narcolepsy was seen already from the spring 2009 onwards, but
there are no epidemiological data on the effect of H1N1 infection or
vaccination [47].
An ongoing caseecontrol study called systematic observational
method for narcolepsy and influenza immunization (SOMNIA) was
designed to assess incidence of narcolepsy in the context of con-
founding influenza infection, increased awareness and vaccinations
[58]. Preliminary results supported a small increase in theincidence of narcolepsy during pre-pandemic period, possibly
because of increased awareness, better diagnostic practices or true
association with H1N1 influenza infection [12,58]. It is to be noted
that in the countries, where the SOMNIA study was finally con-
ducted (Denmark, UK, Canada, Taiwan, the Netherlands, and Spain),
Pandemrix was not used at all or it was used rarely. Therefore, the
power for making inferences about the use of Pandemrix as a risk
factor for developing narcolepsy is very low.
Vaarala et al. have previously identified changes in viral nucle-
oprotein (NP) in Pandemrix and an increased response against NP
in narcoleptic children [23]. Similar changes were not observed
with Arepanrix that included also AS03 adjuvant (17). Subse-
quently, these two vaccines should not be compared to each other
because of their proteomic differences [23]. The viral component of
Pandemrix (D-PAN) was produced in Dresden, Germany. The viral
component of Arepanrix (Q-PAN) was produced in Quebec, Canada
[8]. The purification methods differed from each other, which may
explain the differences in the structure, and also differences related
to increased incidence of narcolepsy in countries where mainly
Pandemrix was used against no or only slightly increased incidence
in countries where Pandemrix was not used. Nevertheless, a recent
animal study implicated the possible role of H1N1 infection itself
affecting the sleep-wake system [20]. A mathematical model sug-
gested that in Norway over half of the people vaccinated against
A(H1N1)pdm09 could have been already infected with the
pandemic virus before the vaccination [59]. Conversely, in a recent
study serological evidence of more frequent H1N1 infections
among vaccinated subjects with narcolepsy was not found [60].
The exact disease mechanism of vaccination-triggered narco-
lepsy remains unknown. Other non-adjuvanted or adjuvanted
pandemic vaccines even with the same AS03 adjuvant are not
associated with increased risk of narcolepsy. The finding of anti-
bodies to hypocretin receptor 2 in a significant proportion of
Finnish Pandemrix-associated narcoleptic patients implicates mo-
lecular mimicry as a possible causative mechanism [61]. These
antibodies may cross-react with influenza NP but their involve-
ment in the pathophysiology of NT1 remains controversial [62].
Data on benefits of the pandemic H1N1 vaccination clearly
outweigh the unexpected and unfortunate risk of narcolepsy. There
was a justifiable reason to believe that A(H1N1)pdm09 would have
been a very aggressive virus with high morbidity and mortality,
especially in younger age groups [63]. Fortunately, the virus proved
to be more similar to seasonal influenza viruses in these terms. It is
still estimated that in the United States alone, A(H1N1)pdm09
caused 270,000 hospitalizations and over 12,000 deaths, most of
the latter occurring in persons under 65 y of age [64]. Hospitali-
zation ratewas increased especially in younger age groups. Globally
the pandemic may have caused more than 200,000 respiratory and
83,000 cardiovascular deaths [65].
The result of increased risk of narcolepsy after Pandemrix
vaccination has been produced in many studies from different
countries. Moreover, the increased risk has been observed in all the
countries where Pandemrix was used in large amounts. Albeit the
fact that the observational studies are affected by various biases,
the association with Pandemrix and narcolepsy remains strong as
seen in our meta-analysis. After recognizing the risk of narcolepsy
associated with Pandemrix vaccine, it is important to continue to
follow the incidence rates in the countries where Pandemrix was
used to monitor the length of the time window during which the
risk was increased. Reports comparing the incidence during pre-
and post-pandemic time periods are valuable even if Pandemrix
was not used, although the increased awareness makes compari-
sons to pre-pandemic period difficult. Further neuroimmunological
studies are required to better understand the link between narco-
lepsy type 1 and Pandemrix vaccine.
Practice points
Epidemiological data from observational studies assessing
risk of narcolepsy after H1N1 pandemic vaccines show that:
1. The risk of narcolepsy appears to have increased in
children, adolescents and to a lesser extent also in adults
after vaccination with Pandemrix.
2. The elevated risk is only associated with Pandemrix-
vaccine and not any other AS03 adjuvanted or any
other pandemic or seasonal vaccine.
3. The risk is associated only with narcolepsy type 1
4. The risk seems to remain at an increased level for two
years after vaccination. However, these data need to be
interpretedwith caution because of the possible biases in
the studies.
5. Narcolepsy is still a rare disease and benefits of vaccines
undoubtedly outweigh the associated risk of narcolepsy
and other autoimmune diseases
6. Observational studies are prone to various biases, e.g.,
confounding by natural H1N1 infection, and ascertain-
ment, recall and selection biases.
Research agenda
Further studies are needed
1. To find the biological explanation for the association
between H1N1 vaccination and narcolepsy type 1
2. To follow the incidence of narcolepsy after the pandemic
time period to determine post-vaccination risk window
3. To better understand the natural history of post Pan-
demrix NT1
4. To recognize in all countries the Pandemrix-vaccine as-
sociation with narcolepsy to compensate victims
accordingly
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